Roche wins FDA clearance for vaginitis PCR diagnostic test
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Roche receives FDA clearance for the cobas® BV/CV assay, enabling fast and highly accurate vaginitis diagnosis
July 24, 2026 8:30 AM EDTThe new PCR test uses clinician-collected or clinician-instructed, self-collected vaginal swab specimens to simultaneously detect organisms associated with Bacterial vaginosis (BV) and Candida vaginitis (CV).This molecular assay can help improve diagnostic accuracy for symptomatic women affected by vaginitis, compared to traditional methods.¹The assay expands the sexual-health testing menu on the cobas® 6800/8800 systems, enabling a broad-range of testing from a single... More
